MARS Calculator
Mutation-Adjusted Risk Score (MARS) stratifies prognostic risk for
adults with advanced systemic mastocytosis.
It uses age, hemoglobin, platelet count, and the number of high-molecular-risk mutations
in SRSF2, ASXL1, and RUNX1.
MARS Score: /5
MARS is a prognostic stratification tool and should be interpreted alongside subtype,
treatment status, organ damage, and specialist hematology assessment.
Published MARS uses 5 parameters:
- age >60 years = 1 point
- hemoglobin <10 g/dL = 1 point
- platelets <100 × 10⁹/L = 1 point
- 1 high-molecular-risk mutation in SRSF2, ASXL1, or RUNX1 = 1 point
- 2 or more of those mutations = 2 points
Total score ranges from 0 to 5 and defines:
- 0–1 = Low risk
- 2 = Intermediate risk
- 3–5 = High risk
The original study reported median overall survival for the combined cohort of about:
- Low risk: not reached
- Intermediate risk: 3.9 years
- High risk: 1.9 years
